ACH-LEVETIRACETAM 500 MG
LEVETIRACETAM : 500 MG · DIN 02399784 · ACCORD HEALTHCARE INC
Health Canada status: MARKETED
What is ACH-LEVETIRACETAM?
ACH-LEVETIRACETAM 500 MG contains LEVETIRACETAM : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02399784, held by ACCORD HEALTHCARE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Mar-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACH-LEVETIRACETAM used for?
Adjunctive therapy in the management of adult (> 18 years of age) patients with epilepsy who are not satisfactorily controlled by conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02399784 |
|---|---|
| Brand name | ACH-LEVETIRACETAM |
| Generic / active ingredient | LEVETIRACETAM : 500 MG |
| Manufacturer | ACCORD HEALTHCARE INC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AX14 LEVETIRACETAM |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Mar-2023 |
| Original market date | 2013-03-20 00:00:00 |
How is it administered?
Initial dose: 1000 mg/day (500 mg bid). May increase by 1000 mg every 2 weeks to a max of 3000 mg/day. Administer in two equally divided doses with or without food. Requires renal adjustment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (section 11 header present but content missing), though typically 15-30°C for such forms.
How is it supplied?
Bottles of 120 tablets.
Contraindications
Hypersensitivity to levetiracetam, other ingredients in the formulation, or component of the container.
Warnings and precautions
Withdraw gradually. Risk of suicidal ideation/behaviour, psychiatric reactions (aggression, anxiety), somnolence, serious skin reactions (SJS, TEN, DRESS), and anaphylaxis/angioedema.
What can be used instead?
Other Canadian products sharing ATC code N03AX14 LEVETIRACETAM. 47 of 109 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-LEVETIRACETAM | 250 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02399776 |
| ACH-LEVETIRACETAM | 750 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02399792 |
| AG-LEVETIRACETAM | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485192 |
| AG-LEVETIRACETAM | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485206 |
| AG-LEVETIRACETAM | 750 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485214 |
| APO-LEVETIRACETAM | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02285924 |
| APO-LEVETIRACETAM | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02285932 |
| APO-LEVETIRACETAM | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02285940 |
| AURO-LEVETIRACETAM | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02375249 |
| AURO-LEVETIRACETAM | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02375257 |
Who else supplies LEVETIRACETAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVETIRACETAM appears in 1082 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.